Apogee Therapeutics: Promising Biologics Developments Justify Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on May 7.

Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Apogee Therapeutics’ promising developments in biologics. The company’s APG808 has shown impressive results in reducing FeNO levels in asthma patients, surpassing the performance of Dupi. This achievement underscores Apogee’s capability to produce best-in-class biologics, even though the focus has shifted to APG777, which is expected to have a competitive clinical profile.
Additionally, Apogee’s APG777 has demonstrated strong pharmacokinetic and pharmacodynamic data, suggesting the potential for extended dosing intervals. The incorporation of YTE half-life extension technology has resulted in a significantly prolonged half-life, and the promising pSTAT6 durability data further supports the potential for less frequent dosing. These advancements position Apogee favorably in the biologics market, justifying a positive outlook and the Buy rating from Tyler Van Buren.

In another report released on May 7, Stifel Nicolaus also reiterated a Buy rating on the stock with a $95.00 price target.